SAN FRANCISCO, Feb. 2, 2016 /PRNewswire/ — Potrero Medical, Inc. today announced the start of the PRESCIENT study, an NIH-sponsored, multi-center observational study using the Accuryn™ Monitoring System to detect the physiological signatures of critical illnesses, including sepsis.
Professor Raul Coimbra, MD, the lead investigator for the study and Chief of the Division of Trauma Surgery at the University of California San Diego, Hillcrest, stated, “We are excited to have enrolled our first patient in the PRESCIENT study which will contribute significantly to the understanding of the physiologic signatures of a variety of critical illnesses in the ICU. This understanding may ultimately lead to earlier detection, and possibly even prediction, of these highly morbid and costly illnesses.”
“This study is intended to test the Accuryn system as a potential new tool for patient monitoring and treatment in the ICU. The device has the potential to provide an early indication of sepsis and, perhaps more importantly, future studies of the additional capabilities of this device could lead to actionable data in guiding resuscitation,” said Phillip Dellinger, MD, Chief of Medicine at Cooper University Health Care in Camden, NJ and Clinical Advisor to Potrero Medical.
Daniel Burnett, MD, Founder and CEO of Potrero Medical stated, “Initiation of this study is another important milestone for us and another step on the path to creating what we believe will be a new gold standard diagnostic platform for the detection and treatment of critical illness. We are thrilled to have the support of Dr. Coimbra, Dr. Dellinger and other leaders in critical care who share our vision for Accuryn™ as a potentially life-saving and cost-saving solution.”
Potrero Medical was awarded $2.25M in SBIR grants from the NIH’s National Institute of General Medical Sciences to run the multi-center PRESCIENT study which is projected to enroll up to 100 patients in the United States.
About the Accuryn™ System:
Accuryn™ is a critical care monitoring system that transforms the traditional urinary catheter into a next-generation diagnostic tool. Accuryn uses proprietary electromechanical designs and advanced software algorithms to deliver automated, real-time actionable data including urine output, core temperature and intraabdominal pressure.
Potrero Medical Inc. previously demonstrated superiority of Accuryn™ in a multi-center randomized clinical study of Accuryn™ against the current gold standard device. The Accuryn™ System is currently an investigational medical device and is not for sale in the United States.
About Potrero Medical, Inc.:
Potrero Medical, Inc., the latest spinout of medical device incubator Theranova, LLC, is headquartered in San Francisco, CA and was founded with a mission is to improve outcomes, reduce costs and expand access to healthcare. For more information about the company, please visit www.potreromed.com.